Official Gene Symbol | Other Aliases |
---|---|
FOXO1 | FKHR, FOXO1A |
Sequence Length (AA) | Molecular Weight (Da) |
---|---|
655 | 69662 |
Protein Name |
---|
Forkhead box protein O1 |
Sources | |
---|---|
UniProt PhosphoSitePlus ® GeneCards |
Human Protein Atlas |
10 | 20 | 30 | 40 | 50 |
MAEAPQVVEI | DPDFEPLPRP | RSCTWPLPRP | EFSQSNSATS | SPAPSGSAAA |
60 | 70 | 80 | 90 | 100 |
NPDAAAGLPS | ASAAAVSADF | MSNLSLLEES | EDFPQAPGSV | AAAVAAAAAA |
110 | 120 | 130 | 140 | 150 |
AATGGLCGDF | QGPEAGCLHP | APPQPPPPGP | LSQHPPVPPA | AAGPLAGQPR |
160 | 170 | 180 | 190 | 200 |
KSSSSRRNAW | GNLSYADLIT | KAIESSAEKR | LTLSQIYEWM | VKSVPYFKDK |
210 | 220 | 230 | 240 | 250 |
GDSNSSAGWK | NSIRHNLSLH | SKFIRVQNEG | TGKSSWWMLN | PEGGKSGKSP |
260 | 270 | 280 | 290 | 300 |
RRRAASMDNN | SKFAKSRSRA | AKKKASLQSG | QEGAGDSPGS | QFSKWPASPG |
310 | 320 | 330 | 340 | 350 |
SHSNDDFDNW | STFRPRTSSN | ASTISGRLSP | IMTEQDDLGE | GDVHSMVYPP |
360 | 370 | 380 | 390 | 400 |
SAAKMASTLP | SLSEISNPEN | MENLLDNLNL | LSSPTSLTVS | TQSSPGTMMQ |
410 | 420 | 430 | 440 | 450 |
QTPCYSFAPP | NTSLNSPSPN | YQKYTYGQSS | MSPLPQMPIQ | TLQDNKSSYG |
460 | 470 | 480 | 490 | 500 |
GMSQYNCAPG | LLKELLTSDS | PPHNDIMTPV | DPGVAQPNSR | VLGQNVMMGP |
510 | 520 | 530 | 540 | 550 |
NSVMSTYGSQ | ASHNKMMNPS | SHTHPGHAQQ | TSAVNGRPLP | HTVSTMPHTS |
560 | 570 | 580 | 590 | 600 |
GMNRLTQVKT | PVQVPLPHPM | QMSALGGYSS | VSSCNGYGRM | GLLHQEKLPS |
610 | 620 | 630 | 640 | 650 |
DLDGMFIERL | DCDMESIIRN | DLMDGDTLDF | NFDNVLPNQS | FPHSVKTTTH |
655 | ||||
SWVSG |
Data source: UniProt
Uniprot Database Entry PhosphoSitePlus ®
loading
Data source: Panorama
View Details (opens in a new window)
Abelin, et al. Mol Cell Proteomics. 2016 May;15(5):1622-41. doi: 10.1074/mcp.M116.058354. Epub 2016 Feb 24. PMID:26912667
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y5 (1+) | 6.2 | 3.1 | 3.6 | 3.6 | 3.9 | 10.5 | 7.2 | 5 | 11.1 | 15 | 15 | 15 |
y7 (1+) | 5.7 | 4.3 | 3.2 | 7.3 | 5 | 8.8 | 9.3 | 6.6 | 9.4 | 15 | 15 | 15 |
y6 (1+) | 6.5 | 3.4 | 2.9 | 6.5 | 3.6 | 7.6 | 9.2 | 5 | 8.1 | 15 | 15 | 15 |
sum | 5.2 | 3.1 | 2.6 | 4.6 | 3.5 | 8.3 | 6.9 | 4.7 | 8.7 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Whiteaker JR, Zhao L, Schoenherr RM, Huang D, Lundeen RA, Voytovich U, Kennedy JJ, Ivey RG, Lin C, Murillo OD, Lorentzen TD, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Reading JJ, Perry CD, Richardson CW, Garcia-Buntley SS, Bocik W, Hewitt SM, Chowdhury S, Vandermeer J, Smith SD, Gopal AK, Ramchurren N, Fling SP, Wang P, Paulovich AG. A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials. Front Oncol. 2023 May 2;13:1168710. doi: 10.3389/fonc.2023.1168710. PMID: 37205196; PMCID: PMC10185886.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y10 (1+) | 24.4 | 15.6 | 17.4 | 26.9 | 19.5 | 13.6 | 36.3 | 25 | 22.1 | 15 | 15 | 15 |
y6 (1+) | 19.9 | 22.3 | 19.9 | 23.2 | 25.4 | 17.7 | 30.6 | 33.8 | 26.6 | 15 | 15 | 15 |
y7 (1+) | 20 | 12.5 | 14.3 | 27.1 | 17.9 | 14.5 | 33.7 | 21.8 | 20.4 | 15 | 15 | 15 |
y8 (1+) | 25.3 | 19.8 | 14.1 | 26.9 | 24.7 | 13.5 | 36.9 | 31.7 | 19.5 | 15 | 15 | 15 |
y16 (2+) | 32 | 21.5 | 20.6 | 31.6 | 27 | 29.2 | 45 | 34.5 | 35.7 | 15 | 15 | 15 |
y7 (2+) | 23.4 | 14.5 | 16.9 | 26.7 | 17.8 | 14.5 | 35.5 | 23 | 22.3 | 15 | 15 | 15 |
y8 (2+) | 15.2 | 13 | 17.5 | 14 | 28.4 | 17.9 | 20.7 | 31.2 | 25 | 15 | 15 | 15 |
sum | 16.6 | 11.1 | 14.8 | 21 | 16.2 | 13.6 | 26.8 | 19.6 | 20.1 | 15 | 15 | 15 |
Data source: Panorama
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Data source: Panorama
Broad Institute-Biologist curated set of targets across a number of important cancer pathways
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y6 (1+) | 5.5 | 6.6 | 7.3 | 14.1 | 5.9 | 8.7 | 15.1 | 8.9 | 11.4 | 15 | 13 | 14 |
y7-98 (2+) | 15.7 | 7.5 | 7 | 10.8 | 6.5 | 5.7 | 19.1 | 9.9 | 9 | 15 | 13 | 14 |
y8-98 (2+) | 15.3 | 6.6 | 9.1 | 13.8 | 6.8 | 8.4 | 20.6 | 9.5 | 12.4 | 15 | 13 | 14 |
y5 (1+) | 10.6 | 5.5 | 13.3 | 11.5 | 5.4 | 16.8 | 15.6 | 7.7 | 21.4 | 15 | 13 | 14 |
y7-98 (1+) | 8.6 | 6.7 | 6.2 | 9 | 6.3 | 7 | 12.4 | 9.2 | 9.4 | 15 | 13 | 14 |
sum | 10.2 | 5.5 | 9.1 | 9.4 | 4 | 8.9 | 13.9 | 6.8 | 12.7 | 15 | 13 | 14 |
Comments